Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The total duration of study per patient is approximately 40 weeks, including 4 to 5 weeks of screening period, 24 weeks of treatment period and 12 weeks of post‐treatment period.
Epistemonikos ID: 2f1bb52663c3d34ae8be69f9cbfc95b38d2af30f
First added on: May 21, 2024